Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. filed this Form 8-K regarding an agreement executed on October 31, 2022, relating to additional funding under its May 3, 2022 Revenue Interest Financing Agreement. The company is developing vonoprazan, including for erosive esophagitis. The filing does not report quarterly or annual operating results.
Material Agreement and Financing
- The company entered into a Joinder and Waiver Agreement with the existing investors, an additional investor, and Hercules Capital, Inc. as administrative and collateral agent.
- The existing investors waived their rights of first offer concerning additional funding under the Revenue Interest Financing Agreement.
- The additional investor joined the financing agreement and extended commitments for up to $15.0 million of approval-related funding and up to $25.0 million of milestone-related funding.
- The approval-related funding could be obtained upon FDA approval of vonoprazan for erosive esophagitis, subject to the applicable agreement terms, with the right to obtain a third-party commitment available through December 31, 2022.
- The milestone-related funding could be obtained upon achievement of a sales milestone, with the right to obtain a third-party commitment available through June 30, 2024.
- The filing does not state that either tranche was funded on October 31, 2022, and the stated amounts represent available or committed additional funding capacity rather than reported cash proceeds.
Financial Metrics, Liquidity, and Debt
The filing provides no revenue, profit, cash flow, margin, cash balance, debt balance, or liquidity metrics. It identifies potential additional financing of up to $40.0 million in aggregate, subject to regulatory, milestone, timing, and contractual conditions. The agreement may create or support additional financial obligations, but the filing does not provide the related repayment, revenue-interest, interest, maturity, or fee terms.
Outlook, Risks, and Unusual Items
- Access to the approval-related funding depends on FDA approval of vonoprazan for erosive esophagitis.
- Access to the milestone-related funding depends on achievement of a specified sales milestone.
- Funding availability and economics are governed by the full Revenue Interest Financing Agreement and Joinder and Waiver Agreement, not fully described in this filing.
- The company stated that it intends to file the Joinder and Waiver Agreement as an exhibit to its 2022 Form 10-K.
- The filing includes a November 1, 2022 press release announcing the agreement; the Regulation FD disclosure is furnished and is not deemed filed under Section 18 of the Exchange Act.
Key Facts for Investors to Verify
- Whether the up to $15.0 million approval-related funding was subsequently committed or funded.
- Whether the up to $25.0 million milestone-related funding was committed or funded and whether the sales milestone was achieved.
- The complete financing terms, including revenue-interest payments, repayment obligations, maturity, security interests, covenants, and fees.
- The status and timing of FDA approval for vonoprazan for erosive esophagitis.
- The company’s subsequent cash balance, liquidity runway, and any additional financing disclosed in later SEC filings.